Immunome, Inc. (IMNM) is a publicly traded Healthcare sector company. As of May 21, 2026, IMNM trades at $21.47 with a market cap of $2.25B and a P/E ratio of -8.89. IMNM moved +9.59% today. Year to date, IMNM is +9.23%; over the trailing twelve months it is +151.52%. Its 52-week range spans $5.15 to $27.65. Analyst consensus is strong buy with an average price target of $35.17. Rallies surfaces IMNM's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies tracks politician and congressional stock disclosures for IMNM, including purchases, sales, transaction dates, owners, and reported trade amounts when available.
| Metric | Value |
|---|---|
| Price | $21.47 |
| Market Cap | $2.25B |
| P/E Ratio | -8.89 |
| EPS | $-2.38 |
| Dividend Yield | 0.00% |
| 52-Week High | $27.65 |
| 52-Week Low | $5.15 |
| Volume | 1.14M |
| Avg Volume | 0 |
| Revenue (TTM) | $4.01M |
| Net Income | $-224.59M |
| Gross Margin | 0.00% |
14 analysts cover IMNM: 0 strong buy, 14 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $35.17.